Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).

Journal article

AIMS/HYPOTHESIS: We estimated the cost-effectiveness of atorvastatin treatment in the primary prevention of cardiovascular disease in patients with type 2 diabetes using data from the Collaborative Atorvastatin Diabetes Study (CARDS). SUBJECTS AND METHODS: A total of 2,838 patients, who were aged 40 to 75 years and had type 2 diabetes without a documented history of cardiovascular disease and without elevated LDL-cholesterol, were recruited from 32 centres in the UK and Ireland and randomly ...

Expand abstract

Authors: Raikou, M; McGuire, A; Colhoun, H; Betteridge, D; Durrington, P

• Journal: Diabetologia
• Volume: 50
• Issue: 4
• Pages: 733-740
• Publication date: 2007-04-01
• DOI: 10.1007/s00125-006-0561-4
• EISSN: 1432-0428
• ISSN: 0012-186X
• Language: English
• Keywords: Anticholesteremic Agents; Quality-Adjusted Life Years; Middle Aged; Diabetes Complications; Aged; Humans; Primary Prevention; Pyrroles; Models, Economic; Male; Cost-Benefit Analysis; CARDS Investigators; Diabetes Mellitus, Type 2; Adult; Cardiovascular Diseases; Female; Heptanoic Acids